ReviewInternational journal of nanomedicine2025
Extracellular Vesicles in Sarcoma: Implications for Tumor Progression and Therapy.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoma, a heterogeneous group of malignancies arising from mesenchymal tissues, poses significant clinical challenges due to its aggressive behavior, early metastasis, and resistance to conventional therapies. Recent advancements highlight the pivotal role of extracellular vesicles (EVs)-nanoscale particles secreted by tumor and stromal cells-in modulating sarcoma progression through intercellular communication within the tumor microenvironment. This review comprehensively examines the multifaceted functions of EVs in sarcoma pathogenesis, focusing on their subtype-specific mechanisms (eg, osteosarcoma, liposarcoma) in promoting epithelial-mesenchymal transition (EMT), angiogenesis, and immune evasion. Additionally, we discuss the emerging potential of EVs as non-invasive biomarkers for early diagnosis and prognosis, as well as their engineered applications in targeted drug delivery and immunotherapy. By integrating cutting-edge research, this article underscores the translational value of EVs in overcoming current therapeutic limitations and provides a roadmap for future investigations into EV-based precision strategies for sarcoma management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.